In Brief: Ephedrine abuse data collection
This article was originally published in The Tan Sheet
Executive Summary
Ephedrine abuse data collection: FDA requests information on the abuse potential, actual abuse, medical usefulness and trafficking of ephedrine and two Rx drug substances dihydroetorphine and remifentanil (Glaxo Wellcome's Ultiva), in a March 18 Federal Register notice. The agency will consider the comments when preparing a statement for the World Health Organization regarding the drugs. WHO is meeting June 23-26 to review the substances. Written comments are due to the agency by April 17...